At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

Dörner concluded: “The LOUiSSe study suggests remibrutinib as a potentially effective oral disease-modifying therapy for Sjögren's, which will be established in longer-term studies.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence 2022; Philadelphia, Pennsylvania, USA: November 10–14

The Assessment of SpondyloArthritis international Society and EULAR have issued up-to-date guidance on the management of radiographic and nonradiographic axial spondyloarthritis.

Ibrahim et al conclude: “Our results strongly support the EULAR inflammatory arthritis pain management guideline recommendation that the initial crucial step in managing RA pain is controlling disease activity.”

For the first study, Laura Coates (University of Oxford, UK) and colleagues analyzed survey responses from 324 EULAR and Emerging EULAR Network (EMEUNET) members representing 23 of the 45 society countries as well as the USA and Mexico.

Rheumatology 2022; doi:10.1093/rheumatology/keac408 RMD Open 2022; 8 : e002322 JAMA Netw Open 2022; 5 : e2226236

Click through for more details on the EULAR recommendations

Research presented at the EULAR 2022 Congress in Copenhagen, Denmark, suggests that maternal and fetal morbidity remain high among pregnant women with systemic lupus erythematosus, despite reductions in mortality in recent decades.

Women with polymyalgia rheumatica may have a small increase in the risk for mortality relative to the general population, but not during the first 20 years after diagnosis, according to research presented at the EULAR 2022 Congress in Copenhagen, Denmark.

Depression in patients with incident rheumatoid arthritis is associated with a sixfold increased risk for mortality, delegates were told at the EULAR 2022 Congress in Copenhagen, Denmark.

Following these positive results, the IL-17A/IL-17F inhibitor progressed to phase 3 trials, some of which were presented at the EULAR 2022 Congress in Copenhagen, Denmark.

medwireNews : Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis (PsA) trials presented at the EULAR 2022 Congress in Copenhagen, Denmark.

Both trials were presented at the EULAR 2022 Congress in Copenhagen, Denmark.

EULAR 2022: Fabian Proft comments on the BE MOBILE 1 and 2 trials of bimekizumab in axial spondyloarthritis.

Anti-adalimumab positivity rates were comparable in the two groups. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group EULAR 2022; Copenhagen, Denmark: 1–4 June Ann Rheum Dis 2022; 81 : 42–43

“COX-2 selective inhibitors might possess a stronger inhibitory effect on radiographic progression as compared to non-selective non-steroids.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group EULAR 2022; Copenhagen, Denmark: 1–4 June Ann Rheum Dis  2022; 81 : 14–15

EULAR 2022: Philippe Carron comments on the BE COMPLETE and BE OPTIMAL trials of bimekizumab in psoriatic arthritis.

Kristensen continued: “These patients do actually get cardiovascular disease and it is a problem.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group EULAR 2022; Copenhagen, Denmark: 1–4 June Ann Rheum Dis  2022; 81 : 20

The studies, presented at the EULAR 2022 Congress in Copenhagen, Denmark, were prompted by the noninferiority ORAL Surveillance trial , which showed an increased risk for MACE with tofacitinib versus TNF inhibitors.